Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.77 |
| ▸ | FNTB | P49356 | 5/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.77 |
| ▸ | TSHR | P16473 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | AR | P10275 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.75 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | SHBG | P04278 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.75 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109857 | 0.99 | FNTA (0.76) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL11785757 | 0.92 | FNTA (0.76) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL8582949 | 0.92 | FNTA (0.76) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL25774026 | 0.89 | FNTA (0.80) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone SCHEMBL794300 | 0.88 | HSD17B10 (0.93) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL9819561 | 0.87 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL4501 | 0.87 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL10301195 | 0.87 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL9819556 | 0.87 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL19644910 | 0.86 | FNTA (0.79) | FNTAFNTBNR3C1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110461315-A | Treatment and Prevention of Cytokine Release Syndrome Using Chimeric Antigen Receptors in Combination with Kinase Inhibitors | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| EP-1996710-B1 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | SALIX PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| CN-101594885-B | Rifaximin anti-rectal dysfunction preparation | 萨利克斯药品公司 | 2017-07-18 | — | — | CN | disclosed |
| EP-2964196-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | Cipla Limited (IN) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | CIPLA LIMITED (MH) | 2016-01-07 | — | — | US | disclosed |
| US-20150196488-A1 | Topical Foam Composition | CIPLA LIMITED (IN) | 2015-07-16 | — | — | US | disclosed |
| US-8987292-B2 | Rifaximin anti-rectal dysfunction preparation | SALIX PHARMACEUTICALS, LTD. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2014135891-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | CIPLA LIMITED (IN) | 2014-09-12 | — | — | WO | disclosed |
| EP-2148657-B1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INT LTD (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-20130315998-A1 | Topical Foam Composition | CIPLA LIMITED (IN) | 2013-11-28 | — | — | US | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0719145-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995032715-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0477195-A1 | SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS | THE UPJOHN COMPANY (US) | 1992-04-01 | — | — | EP | disclosed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4432964-A | Topical composition containing steroid in two forms released independently from polymeric carrier | ALZA CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0088462-A2 | Anti-inflammatory and rheumatic composition containing organophosphonate and steroid | THE PROCTER & GAMBLE COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| US-3966778-A | Production of 21-phosphate corticords having unprotected hydroxyl radicals at least at the 17α- and 21-position | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | SI, CROCC, FABP2 | FNTA 26/4885FNTB 36/4885NR3C1 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.